IQWiG offers medical device manufacturers a model contract to simplify confidential use of study documents

06

Dec 2017

The German Institute for Quality and Efficiency in Health Care (IQWiG) evaluates about five to ten treatment methods that require medical devices. Previously, for example, laboratory tests for the detection of metabolic diseases, laser for the removal of prostate tissue, stents and monitoring systems for cardiac patients were tested. Health technology assessments (HTAs) are typically ordered by the Federal Joint Committee (G-BA).

For the purpose of benefit assessments, all relevant available information should be taken into account, including studies carried out by the industry. According to the IQWiG director Jürgen Windeler, it is important that complete information is provided by manufacturers and that results can be passed further to assure transparency. This concerns particularly study reports that are available earlier than in journal publications and contain more detailed information.

To regulate the conditions under which information provided by manufacturers can be used and make it available to third parties, IQWiG has now drafted a model contract in the agreement with the relevant manufacturers' associations. The model contract can serve as a basis for bilateral agreements with the IQWiG for manufacturers of medical devices. It offers advantages for both sides: confidential information such as company and business secrets remain protected, while IQWiG can use and publish the methods and results of the studies.

The concrete procedure comprises two stages:

  • After signing the contract, the manufacturer sends a list of all potentially relevant studies to the IQWiG.
  • The IQWiG then requests documents with detailed information from the manufacturer for the studies it deems relevant. Study protocols and final reports are of particular interest.

A comparable model contract for the evaluation of pharmaceuticals has existed for ten years and is accepted by almost all manufacturers.

The template for the contract is available in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more